ERYTECH reports positive top-line Phase III results from clinical study with GRASPA® in Acute Lymphoblastic Leukemia admERY September 30, 2014 Newsroom ERYTECH reports positive Phase III results from its pivotal study with GRASPA® in Acute Lymphoblastic Leukemia. You Might Also Like ERYTECH Provides Business Update and Reports Financial Results for the Third Quarter of 2020 November 5, 2020 ERYTECH Receives USPTO Notice of Allowance for Patent Covering ERYCAPS Immunotherapy Technology March 15, 2016 ERYTECH to Present at Jefferies 2019 HealthCare Conference in London November 14, 2019
ERYTECH Provides Business Update and Reports Financial Results for the Third Quarter of 2020 November 5, 2020
ERYTECH Receives USPTO Notice of Allowance for Patent Covering ERYCAPS Immunotherapy Technology March 15, 2016
